NERV Minerva Neurosciences Inc

Price (delayed)

$3.49

Market cap

$166.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$36.24

Enterprise value

$201.89M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva’s goal is to transform the lives of patients with improved therapeutic options, ...

Highlights
Minerva Neurosciences's equity has increased by 16% QoQ
The company's quick ratio rose by 9% QoQ

Key stats

What are the main financial stats of NERV

NERV stock price

How has the Minerva Neurosciences stock price performed over time
Intraday
-8.4%
1 week
0.14%
1 month
-27.89%
1 year
67.25%
YTD
-13.18%
QTD
-37.12%

Financial performance

How have Minerva Neurosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.14M
Net income
-$394.35M
Gross margin
N/A
Net margin
N/A
NERV's operating income has dropped by 117% year-on-year and by 26% since the previous quarter
The company's net income rose by 5% QoQ

Price vs fundamentals

How does NERV's price correlate with its fundamentals

Growth

What is Minerva Neurosciences's growth rate over time

Valuation

What is Minerva Neurosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 2.1% since the previous quarter
Minerva Neurosciences's equity has increased by 16% QoQ

Efficiency

How efficient is Minerva Neurosciences business performance
Minerva Neurosciences's return on assets has increased by 24% QoQ
The return on invested capital is up by 20% since the previous quarter

Dividends

What is NERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NERV.

Financial health

How did Minerva Neurosciences financials performed over time
The total assets is 68% less than the total liabilities
Minerva Neurosciences's total liabilities has decreased by 14% QoQ
Minerva Neurosciences's current ratio has increased by 14% QoQ
The debt is 128% more than the equity
The debt to equity has surged by 85% year-on-year but it has declined by 17% since the previous quarter
Minerva Neurosciences's equity has increased by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.